Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,203.90 | 28.80 | 0.35% |
CAC 40 | 7,573.76 | 37.50 | 0.50% |
DAX 40 | 22,271.67 | 29.22 | 0.13% |
Dow JONES (US) | 40,002.16 | 111.34 | -0.28% |
FTSE 100 | 8,417.34 | 2.09 | 0.02% |
HKSE | 21,971.96 | 8.78 | -0.04% |
NASDAQ | 17,173.86 | 209.08 | -1.20% |
Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
S&P 500 | 5,484.23 | 40.98 | -0.74% |
S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
SSE Composite Index | 3,288.41 | 6.65 | -0.20% |